Posters

Clinical assessment of a new central topography method to assist premium intraocular lens selection

Poster Details

First Author: M.Lawless AUSTRALIA

Co Author(s):    C. Hodge                    

Abstract Details

Purpose:

A novel technology to assess visually relevant central corneal topography (VRCT) (anterior axial power maps and total axial power maps) is introduced. It is intended to aid the surgeon’s clinical decision regarding the potential implantation of a premium intraocular lens (IOL). The purpose of the study is to determine the clinical relevance of the new technology.

Setting:

Private clinic, Sydney Australia

Methods:

De-identified VRCT (axial and corneal power maps) and IOLMaster 700 biometry and keratometry data of 90 eyes of 50 patients who had previously undergone successful cataract surgery and IOL insertion were provided to a masked observer (ophthalmic surgeon). The surgeon was asked to determine the appropriateness of a premium IOL in the given eyes given the available information. Results were classified as positive, possible or negative for toric or multifocal IOLs. The findings were separately matched against the actual surgical procedure.

Results:

Based on biometry and VRCT alone, the masked observer identified 90% (81) of eyes as green for toric IOL insertion. Of these eyes, 75.3% proceeded. 9 eyes required more information (orange) with 5 of these eyes subsequently diagnosed with dry eye or not suitable.   56.7% (51) eyes were considered green for multifocal IOLs with 10 eyes proceeding. 29 eyes of this cohort were subsequently considered ineligible for multifocal IOL due to separate considerations. 36.7% were orange and required more information and 6.7% were red and inappropriate for multifocal IOLs. No eye considered red on VRCT proceeded to multifocal implantation.

Conclusions:

The combination of VRCT and biometry data appears to support the intended role of identifying central corneal irregularity caused by disease or dry eye and assisting the clinical based decision of IOL choice. This information provides an excellent platform for further investigations.

Financial Disclosure:

None